Recent Updates
Recently added Catalysts

ctDNA testing

Phase 2

Muscle Invasive Bladder Cancer (MIBC) | Oncology |Natera, Inc.|Trials Updated: Nov 18, 2026

ctDNA testing development status

Highest phase Phase 2
Registered trials 2 across 2 sponsors since Jul 2025

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLEDDMC
Total Trials1
Total Enrollment150

FDA Designations

No designations recorded

ctDNA testing clinical trials

ctDNA testing · 1 trial · 1 indication

Phase 2 1
NCT07946601Genomic ctDNA-Informed De-escalation And Neoadjuvant Chemotherapy Omission in CystectomyMuscle Invasive Bladder Cancer (MIBC)
NOT YET_RECRUITING150 Analytics
PHASE2NOT YET_RECRUITING
Genomic ctDNA-Informed De-escalation And Neoadjuvant Chemotherapy Omission in Cystectomy
Muscle Invasive Bladder Cancer (MIBC)Unlock trial analytics

Study Endpoints

Primary Endpoints

Recurrence free survival (RFS)
2 years

RFS is defined as the time from the date of cystectomy in ctDNA-negative MIBC participants to the date of first documented radiological recurrence per RECIST v1.1 or death, whichever occurs first.

Secondary Endpoints

Overall survival (OS)
at 2 years
Overall survival
at 5 years
Rate of pathological complete response (pCR)
at day 0
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeSUPPORTIVE_CARE

Treatment Arms

ArmTypeDescription
ctDNA-negative MIBCEXPERIMENTALThere will be a pilot lead-in phase for the first 30 participants who are eligible due to the risks associated. Participants who are newly diagnosed with MIBC who are candidates for radical cystectomy will undergo baseline ctDNA test. Participants who are confirmed to be ctDNA negative will be enrolled in the study and will proceed directly to radical cystectomy without neoadjuvant chemotherapy (NAC). After surgery, participants will undergo standard of care assessments.

Interventions

NameTypeDescription
ctDNA testingDIAGNOSTIC_TESTNewly diagnosed MIBC participants who are candidates for radical cystectomy will first undergo baseline ctDNA testing to see if they are ctDNA negative. If the participant is confirmed ctDNA negative, they will be enrolled in the study and undergo radical cystectomy without neoadjuvant chemotherapy.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Histologically confirmed muscle-invasive urothelial carcinoma of the bladder (cT2- T4aN0M0). * Planned for radical cystectomy with curative intent. * Negative for ctDNA using a validated, tumor-informed assay (Natera Signatera) from a blood sample collected prior to any system...

Countries:United States
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWNov 18, 2026NCT07946601New Trial Detected: Not Yet Recruiting